UNSPSC 51412902: Nicofuranose

This classification denotes a vasodilating agent and anti-lipidemic agent with the molecular formula C30H24N4O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GF99P6327K, chemically known as 1,3,4,6-tetra-o-nicotinoyl-d-fructofuranose but generally known as nicofuranose, which bears US NIH Compound Identifier 25495. European Medicines Agency schedules Nicofuranose in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09237MIG.

UNSPSC 51412902 Nicofuranose is a Commodity code that captures pharmaceutical active pharmaceutical ingredients and specialty medications sourced by state and local health authorities, emergency services, and multistate purchasing cooperatives. Recent solicitations show state and local governments buying advanced life support medications, generic pharmaceuticals, and over-the-counter products through formal competitive procurement processes. The City of Tampa's Fire Rescue Department procures specific injectable medications (epinephrine, labetalol, adenosine, diltiazem) for emergency response; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) establishes statewide contracts for generic multi-source pharmaceuticals and OTC products; and the Texas Health and Human Services Commission is exploring direct-to-manufacturer pharmacy supply models. Issuing bodies include municipal fire and rescue departments, state health and human services agencies, and cooperative purchasing alliances that aggregate demand across multiple state and local jurisdictions.

Activity under this code spans Florida, Minnesota, Texas, and participating MMCAP states including Oregon. Representative recent opportunities include the City of Tampa's sealed-bid IFB (26P00188) for Advanced Life Support Medications with a response deadline of April 8, 2026 and an estimated contract value of $40,000, requiring four specific medication line items with nine-month minimum expiration dates and one-year firm pricing with renewal options; the Minnesota MMCAP's RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, establishing two-year contracts effective July 1, 2026, with pricing weighted at 75 percent of evaluation and compliance with cGMP and DSCSA required; and the Texas HHS Commission's RFI (HHS0017013) posted April 3, 2026, exploring direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The Tampa solicitation includes a 5 percent SLBE bid discount not to exceed $10,000, and vendors must provide Safety Data Sheets compliant with OSHA standards and WCAG 2.2 Level AA accessibility documentation.